Tesamorelin's research value depends on both its GHRH-fragment backbone and its distinctive N-terminal modification being correctly synthesized, which makes lot-level analytical testing especially informative.
Reversed-phase HPLC
HPLC resolves the fully modified peptide from unmodified fragment and other synthesis byproducts, with the purity figure interpreted per understanding HPLC purity.
Mass spectrometry for identity
The added trans-3-hexenoic acid group described in the chemistry article shifts the molecule's mass in a way mass spectrometry can directly confirm, distinguishing correctly modified tesamorelin from unmodified GHRH-fragment analogs such as sermorelin — see HPLC vs. mass spectrometry.
Why the modification matters analytically
Because tesamorelin's enzymatic-degradation resistance is the entire basis of its research utility (detailed in its mechanism of action), a lot lacking the full modification would not behave as expected in a stability-dependent protocol even if it appeared superficially similar.
Documentation to expect
A lot-specific certificate of analysis with HPLC purity and mass-spec identity — see how to read a CoA.
Product page: Tesamorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.